Shanghai Shyndec Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Yong Liu

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	less than a year
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	2yrs
Gemiddelde ambtstermijn bestuur	3.6yrs

Recente managementupdates

Recent updates

CEO

Yong Liu (55 yo)

less than a year

Tenure

Mr. Yong Liu is Vice Chairman of the Board of Shanghai Shyndec Pharmaceutical Co., Ltd. from April 28, 2021 and serves as President Since September 2024.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Yong Liu	Vice Chairman of the Board & President	less than a year	geen gegevens	geen gegevens
Xian Lin Li	VP & General Counsel	2.6yrs	CN¥1.43m	0.0015% CN¥ 241.8k
Dongsong Wei	VP & Secretary of the Board of Directors	13.3yrs	CN¥1.46m	0.0015% CN¥ 241.8k
Feng Ni	Vice President	2yrs	CN¥914.60k	0.0015% CN¥ 241.8k
Jing Zu	Chief Financial Officer	less than a year	CN¥344.90k	geen gegevens

2.0yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 600420 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Yong Liu	Vice Chairman of the Board & President	3.6yrs	geen gegevens	geen gegevens
Yingqi Li	Independent Director	2yrs	CN¥240.00k	geen gegevens
Peng Wang	Director	2yrs	geen gegevens	geen gegevens
Ru Li	Director	2yrs	geen gegevens	geen gegevens
Zenghe Dong	Chairman	5.8yrs	geen gegevens	geen gegevens
Xiangdong Yu	Supervisor	5.8yrs	geen gegevens	0.0015% CN¥ 241.8k
Kan Tian	Independent Director	5.8yrs	CN¥240.00k	geen gegevens
Yonggang Xing	Chairman of the Supervisory Board	5yrs	geen gegevens	geen gegevens
Shuyuan Wei	Director	4.5yrs	geen gegevens	geen gegevens
Fanhong Wu	Independent Director	3.6yrs	CN¥240.00k	geen gegevens
Yonghua Zuo	Supervisor	2yrs	geen gegevens	geen gegevens

3.6yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 600420 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.6 jaar).

Shanghai Shyndec Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

Less than half of directors are independent

Less than half of directors are independent

Recent updates

Third quarter 2024 earnings released: EPS: CN¥0.18 (vs CN¥0.16 in 3Q 2023)

Investor sentiment deteriorates as stock falls 15%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 29, 2024

Investor sentiment improves as stock rises 19%

Second quarter 2024 earnings released: EPS: CN¥0.29 (vs CN¥0.13 in 2Q 2023)

Investor sentiment improves as stock rises 17%

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 29, 2024

Shanghai Shyndec Pharmaceutical Co., Ltd., Annual General Meeting, May 28, 2024

First quarter 2024 earnings released: EPS: CN¥0.25 (vs CN¥0.15 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Full year 2023 earnings released: EPS: CN¥0.54 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 30, 2024

Full year 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in FY 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Mar 30, 2024

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.14 in 2Q 2022)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2023 Results on Aug 29, 2023

First quarter 2023 earnings released: EPS: CN¥0.15 (vs CN¥0.076 in 1Q 2022)

Investor sentiment improves as stock rises 20%

Full year 2022 earnings released: EPS: CN¥0.61 (vs CN¥0.55 in FY 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd. announced that it has received CNY 1.199999999 billion in funding from China National Pharmaceutical Group Corporation

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0.20 (vs CN¥0.20 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.14 (vs CN¥0.20 in 2Q 2021)

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

Shanghai Shyndec Pharmaceutical Co., Ltd.(XSSC:600420) dropped from S&P Global BMI Index

First quarter 2022 earnings released: EPS: CN¥0.076 (vs CN¥0.21 in 1Q 2021)

Less than half of directors are independent

Full year 2021 earnings released: EPS: CN¥0.55 (vs CN¥0.63 in FY 2020)

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.30 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

Second quarter 2021 earnings released: EPS CN¥0.20 (vs CN¥0.19 in 2Q 2020)

First quarter 2021 earnings released: EPS CN¥0.21 (vs CN¥0.13 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.63 (vs CN¥0.62 in FY 2019)

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day low: CN¥8.47

New 90-day low: CN¥9.01

New 90-day low: CN¥9.42

New 90-day high: CN¥10.68

Third quarter earnings released

New 90-day low: CN¥9.49

First half earnings released

New 90-day high - CN¥10.64

Shanghai Shyndec Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 28, 2020

CEO

Tenure

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd